Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...

AstraZeneca completes acquisition of biotech company, EsoBiotec: Cambridge, UK Wednesday, May 21, 2025, 09:00 Hrs [IST] AstraZeneca announced the successful completion of the acqu ...

The acquisition, initially announced in March, sees AstraZeneca pay USD425 million up front, with an additional USD575 million in potential milestone payments, bringing the total consideration to up ...

AstraZeneca has successfully completed the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell ...

Acquisition of EsoBiotec completed AstraZeneca today announced the successful completion of the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has ...